Table A2.
Validation of Final Multivariable Model for Acute GVHD in Chronic Myeloid Leukemia
Variable | Grade 2-4 Acute GVHD
|
Grade 3-4 Acute GVHD
|
||||
---|---|---|---|---|---|---|
RR | 95% CI | P | RR | 95% CI | P | |
For recipients age 18-39 years | ||||||
Bone marrow graft | 1.0 | 1.0 | ||||
Peripheral blood stem-cell graft | 1.34 | 0.945 to 1.90 | .1007 | 1.10 | 0.65 to 1.87 | .7233 |
For recipients age 40+ years | ||||||
Bone marrow graft | 1.0 | 1.0 | ||||
Peripheral blood stem-cell graft | 0.81 | 0.58 to 1.11 | .1944 | 1.01 | 0.63 to 1.64 | .9599 |
Age for recipients of bone marrow transplants, years | ||||||
18-39 | 1.0 | 1.0 | ||||
40+ | 1.55 | 1.18 to 2.03 | .0016 | 1.29 | 0.86 to 1.93 | .2179 |
Age for recipients of peripheral-blood stem-cell transplants, years | ||||||
18-39 | 1.0 | 1.0 | ||||
40+ | 0.93 | 0.63 to 1.38 | .7211 | 1.19 | 0.65 to 2.16 | .5772 |
Race | ||||||
Asian/Hispanic | 1.0 | 1.0 | ||||
White/Black | 1.31 | 0.95 to 1.79 | .0956 | 0.99 | 0.64 to 1.52 | .9516 |
Karnofsky performance score at transplant | ||||||
90-100 | 1.0 | 1.0 | ||||
0-80 | 1.46 | 1.09 to 1.96 | .0110 | 1.58 | 1.03 to 2.42 | .0370 |
Conditioning regimen | ||||||
BuCy ± other | 1.0 | 1.0 | ||||
CyTBI ± other | 1.44 | 1.13 to 1.84 | .0035 | 0.85 | 0.57 to 1.27 | .4324 |
Recipient-donor cytomegalovirus status | ||||||
≥ 1 positive | 1.0 | 1.0 | ||||
Both negative | 1.37 | 1.07 to 1.74 | .0117 | 1.53 | 1.07 to 2.19 | .0190 |
Abbreviations: GVHD, graft-versus-host disease; RR, relative risk; BuCy ± other, busulfan and cyclophosphamide with or without additional agents; CyTBI ± other, cyclophosphamide and total body irradiation with or without additional agents.